Recombinant Alpha-1-antitrypsin

Summary

Recombinant Alpha-1-antitrypsin (rAAT) is a recombinantly produced form of the endogenous serine protease inhibitor alpha-1-antitrypsin, intended as an alternative to plasma-derived AAT augmentation therapy. It is being investigated for Alpha-1-antitrypsin deficiency (AATD), graft-versus-host disease (GvHD), type 1 diabetes, and inflammatory conditions. Unlike plasma-derived AAT products (e.g., Prolastin, Zemaira), rAAT is not yet approved and remains in clinical trials.

Mechanism of Action

Inhibits neutrophil elastase and other serine proteases by acting as a 'suicide substrate', forming a covalent complex that irreversibly neutralizes protease activity, thereby protecting lung tissue from proteolytic damage and reducing inflammation.

Routes of Administration

Goals & Uses

• Type 1 diabetes / islet protectionMetabolic/autoimmune DiseaseLow
• Lung inflammation and emphysema preventionPulmonaryModerate
• Graft-versus-host disease (GvHD) prevention/treatmentImmunomodulationModerate
• Alpha-1-antitrypsin deficiency (AATD) augmentationGenetic/metabolic DiseaseModerate
• Inflammatory bowel diseaseGastroenterologyLow

Contraindications

• Hypersensitivity to AAT or excipientsAllergy/immunologyHigh
• IgA deficiency with anti-IgA antibodiesImmunologicalModerate
• Active malignancy requiring immunosuppression cautionOncologyModerate

Adverse Effects

• AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
• HeadacheNeurologicCommonPain in the head or upper neck
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Infusion-related reactionsHypersensitivityUncommon
• DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
• Immunogenicity / antibody formationImmunologicUnknown

Drug Interactions

• Other protease inhibitorsLow
• Immunosuppressants (e.g., corticosteroids, tacrolimus)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Renal or hepatic impairmentOrgan DysfunctionRelative

Regulatory Status

• European UnionInvestigationalPlasma-derived AAT products are EMA-approved; recombinant forms remain investigational. Orphan designation explored for AATD.
• United StatesInvestigationalNo rAAT product approved by FDA; plasma-derived AAT products (Prolastin-C, Zemaira, Aralast NP) are approved for AATD. rAAT holds investigational status in multiple IND-stage trials.
• United KingdomInvestigationalMHRA recognizes plasma-derived AAT; recombinant forms are not approved as of knowledge cutoff.

Plasma-derived AAT products are FDA-approved for AATD; recombinant forms (e.g., produced in yeast, CHO cells, or transgenic systems) are investigational. No rAAT product has received FDA or EMA approval as of the knowledge cutoff. Orphan drug designation has been sought for some rAAT programs.

Evidence & Sources

No sources recorded yet.